Bastion Therapeutics was a biotech co-founded by Nia Emami.
Our mission was to develop novel Treg cell therapies for inflammatory disorders with high unmet need.
We used our proprietary GRIT™ platform to engineer Tregs that modulate the immune system and overcome key limitations of earlier approaches.
Our goal was to create therapies that are safe, durable, and truly effective for patients.
Bastion Therapeutics concluded operations in December 2024.
Company Details
- Employees
- 3
- Address
- 58 Wood Lane, Scale Space,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.bastion-tx.com/
- Keywords
- Coya Therapeutics.
- HQ
- London
Bastion Therapeutics Questions
Bastion Therapeutics's website is https://www.bastion-tx.com/
Bastion Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/bastion-therapeutics
Bastion Therapeutics has
3 employees.
View email and phone details for 3
employees at Bastion Therapeutics.
Bastion Therapeutics's industry is
Biotechnology Research
Bastion Therapeutics's top competitors are
Coya Therapeutics, Inc.,
Abata Therapeutics,
Gentibio,
Resilient Collective,
Cellenkos, Inc.,
Mesenbio,
Sonoma Biotherapeutics, Inc.,
Quell Therapeutics,
Celentyx Ltd,
Senya Therapeutics.
Bastion Therapeutics's categories are Biotechnology Research
